Fractyl Health, Inc. Common Stock
HealthcareNASDAQ:GUTS · NASDAQ Global Market
+$0.13 today
Vol 3.06M · Avg 2.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1490.3%
avg -264.9%
ROIC
-89.5%
avg -146.9%
ROA
-116.1%
avg -117.8%
Analysis
ROIC is currently the strongest return metric at -89.5% versus its period average of -146.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Harith Rajagopalan | Co-Founder, Chief Executive Officer & Director | $976,422.00 | — | 49 | $540,557.00 | 0.75% |
Jay D. Caplan BSEE | Co-Founder, Chief Product Officer & President | $666,858.00 | — | 64 | $845,226.00 | 1.17% |
Sarah S. Toomey | General Counsel & Corporate Secretary | $638,648.00 | — | 51 | $743,913.00 | 1.03% |
Lara Smith Weber | Chief Financial Officer & Treasurer | $580,985.00 | — | 51 | $20,000.00 | 0.03% |
Brian Luque | Head of Investor Relations & Corporate Development | — | — | — | — | — |
Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical | — | — | — | — | — |
Mike Zumdahl | Senior Vice President of Market Access & Commercial Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$127,816.88
Sells
0
$0.00
Net Sentiment
+$127,816.88
Net buying
Most Active
Rajagopalan Harith
2 transactions
Analysis
Insiders reported 5 buys worth $127,816.88 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $127,816.88. Rajagopalan Harith was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +225.2% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +225.2% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
Metagenomi, Inc. Common Stock
MGX
$45.18M
aTyr Pharma, Inc.
ATYR
$43.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages GUTS?
Fractyl Health, Inc. Common Stock (GUTS) lists 7 active executives. The top listed executive is Lara Smith Weber, Chief Financial Officer & Treasurer.
Are GUTS insiders buying or selling?
Recent insider activity shows net buying of $26.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.